CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today... | May 12, 2022

Related Keywords

United Kingdom ,Wien ,Austria ,Texas ,United States ,Massachusetts ,California ,Vienna ,Cambridge ,Cambridgeshire ,Switzerland ,London ,City Of ,San Francisco ,Susan Kim ,Swaminathanp Iyer ,Rachel Eides ,Hall Strauss ,Division Of Cancer Medicine ,Vertex Pharmaceuticals ,University Of Texas Md Anderson Cancer Center ,Congress Center ,European Hematology Association ,Exchange Commission ,Viacyte Inc ,Therapeutics Inc ,Department Of Lymphoma Myeloma ,Globenewswire Inc ,Hematology Association ,Messe Wien Exhibition ,Escalation Study ,Targeted Allogeneic ,T Cell Malignancies ,Cancer Medicine ,Cancer Center ,Gene Therapy ,Private Securities Litigation Reform Act ,Crispr Therapeutics Ag Stock Exchange ,News ,Information ,Press Release ,End ,Bay ,022 ,Rispr ,Herapeutics ,Iopharmaceutical ,Company ,Ocused ,N ,Reating ,Ransformative ,Medicines ,Or ,Erious Crsp Ch0334081137 ,